Consequently, the use of either acetylcholine esterase (AChE) inhibitors or selective agonists of certain nAChR subtypes aimed to enhance cholinergic signaling has been suggested as a current medication for symptomatic treatment of AD patients (Russo et al., 2014). Here, CHRNA4 is linked to Alzheimer disease.